Edition:
India

Camurus AB (CAMX.ST)

CAMX.ST on Stockholm Stock Exchange

116.20SEK
6:00pm IST
Change (% chg)

-25.80kr (-18.17%)
Prev Close
142.00kr
Open
116.00kr
Day's High
119.00kr
Day's Low
111.60kr
Volume
377,486
Avg. Vol
35,017
52-wk High
147.80kr
52-wk Low
103.00kr

Latest Key Developments (Source: Significant Developments)

Camurus Q3 operating loss widens to SEK ‍67.1​ million
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - CAMURUS AB :Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO.Q3 OPERATING LOSS SEK ‍-67.1​ MILLION VERSUS LOSS SEK 16.6 MILLION YEAR AGO.  Full Article

Camurus Q2 loss after tax narrows to SEK 20.6 million
Thursday, 14 Jul 2016 

Camurus AB : Q2 revenue 25.8 million Swedish crowns ($3 million) versus 22.7 million crowns year ago .Q2 loss after tax 20.6 million crowns versus loss 115.2 million crowns year ago.  Full Article

Camurus: Safety and local tolerability of CAM2029 in Phase 2 study was good
Tuesday, 12 Jul 2016 

Camurus AB : Announces completion of Phase 2 study of CAM2029 in patients with acromegaly and neuroendocrine tumors . In present study treatment with CAM2029 resulted in therapeutic blood-levels of octreotide over four weeks . Safety and local tolerability of CAM2029 was good and consistent with marketed reference product Sandostatin Lar .As next step looks forward to initiation of planned Phase 3 trials by collaborator Novartis.  Full Article

Camurus: Results from Phase 2 trial of CAM2032 in patients with prostate cancer
Tuesday, 21 Jun 2016 

Camurus AB : Announces results from a Phase 2 trial of CAM2032 in patients with prostate cancer . Positive results from a repeat-dose Phase 2 trial of two dose levels of leuprolide FluidCrystal injection depot (CAM2032 3.75 mg and 7.5 mg) and the active comparator, Eligard 7.5 mg, in patients with prostate cancer . Data from Phase 2 trial demonstrated comparable pharmacokinetic profiles for three treatments .Further development of CAM2032, including potential partnerships, is currently being evaluated.  Full Article

Camurus swings to Q1 net loss of 19.4 million Swedish crowns
Tuesday, 17 May 2016 

Camurus AB : Q1 net revenue 20.2 million Swedish crowns ($2.45 million) versus 58.6 million crowns year ago . Q1 loss after tax 19.4 million crowns versus profit 10.2 million crowns year ago .Board of directors has not changed its outlook on future developments in relation to outlook published in year end report 2015.  Full Article

Camurus: positive results from Phase 2 study with CAM2038
Wednesday, 11 May 2016 

Camurus AB : Braeburn Pharmaceuticals and Camurus announce positive results from Phase 2 opioid challenge study with CAM2038 in subjects with opioid use disorder . Results from present Phase 2 study demonstrate that CAM2038 blocks effectively subjective effects of opioid challenges with hydromorphone .CAM2038 was well tolerated across course of treatment.  Full Article

Camurus signs distribution agreement with R-PHARM US for episil
Thursday, 21 Apr 2016 

Camurus AB:Says has granted R-PHARM US exclusive license and distribution rights for episil oral liquid in the US.  Full Article

Camurus and Braeburn Pharmaceuticals announce enrollment goals reached in 2 pivotal Phase 3 trials of CAM2038
Tuesday, 5 Apr 2016 

Camurus AB:Braeburn Pharmaceuticals and Camurus announce enrollment goals reached in two pivotal Phase 3 trials of CAM2038 for treatment of opioid dependence.Trials were designed to establish clinical efficacy and long-term safety of both weekly (q1w) and monthly (q4w) formulations.  Full Article

BRIEF-Camurus Q3 operating loss widens to SEK ‍67.1​ million

* Q3 NET REVENUE SEK ‍12.5​ MILLION VERSUS SEK 30.5 MILLION YEAR AGO